NOURIGEN LABS, LLC – Trademark Portfolio
Entity Type: 16
NOURIGEN LABS, LLC holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 41 (Education & Entertainment) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include AGELESSLX, NOURIGEN LABS, and AGELESS TRANSFORMATIONS. The owner is based in MISSOULA, MT.
135 WEST MAIN ST., STE. B
MISSOULA, MT 59892
Showing of trademarks Trademarks
Trademark Classifications
NOURIGEN LABS, LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Education; providing of training; entertainment; sporting and cultural activities
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does NOURIGEN LABS, LLC have?
NOURIGEN LABS, LLC has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.
What trademark classes does NOURIGEN LABS, LLC file in?
NOURIGEN LABS, LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are NOURIGEN LABS, LLC's most well-known trademarks?
NOURIGEN LABS, LLC's registered trademark portfolio includes well-known marks such as AGELESSLX, NOURIGEN LABS, and AGELESS TRANSFORMATIONS. These are among 3 currently registered trademarks in the portfolio.
What is NOURIGEN LABS, LLC's trademark registration success rate?
NOURIGEN LABS, LLC has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.